A nurse reviews a patient's medication list.
The patient is taking a drug that is highly protein-bound (greater than 89 percent). Which of these best explains the significance of highly protein-bound medications?

Choice A rationale

Administering omalizumab despite a reported allergy to peanuts is potentially unsafe because omalizumab has a black box warning for anaphylaxis, which can be life-threatening. While the peanut allergy may not directly contraindicate omalizumab, it suggests a heightened risk for severe allergic reactions due to atopy. Prudence dictates consulting the provider for risk assessment, skin testing, or alternative treatments, prioritizing patient safety before injection.

Choice B rationale

Omalizumab carries a risk of anaphylaxis, which can occur after any dose, including the first. A documented allergy, particularly to a common and potent allergen like peanuts, indicates a predisposition to hypersensitivity reactions (atopy). The most appropriate and safest nursing action is to withhold the injection and notify the healthcare provider to evaluate the risk and determine if the medication is still indicated or if precautions, such as desensitization or alternative therapy, are required.

Choice C rationale

Asking about recent anaphylaxis symptoms does not mitigate the potential risk of a future, severe reaction to omalizumab, which has a boxed warning for anaphylaxis. While a history of severe allergies is pertinent, the immediate safety concern is the risk of a severe hypersensitivity reaction to the drug itself. The nurse must address the reported allergy and the drug's known risks before proceeding with administration.

Choice D rationale

While ensuring an EpiPen is available is a precautionary measure for any patient receiving omalizumab due to the risk of anaphylaxis, it does not address the underlying concern of the documented peanut allergy, which might increase the patient's overall allergic predisposition. The nurse's first action must be to ensure the drug is safe to administer, which means consulting the provider about the allergy before administration.

Choice A rationale

Hyperplasia is defined as an increase in the number of cells in a tissue or organ. For example, the proliferation of glandular cells in the female breast during pregnancy. This differs from the described change where one cell type (ciliated columnar) is replaced by a different, more resilient cell type (squamous), without necessarily increasing cell number.

Choice B rationale

Anaplasia describes the loss of cellular differentiation, a hallmark of malignancy where cells revert to a more primitive, undifferentiated state. The resulting cells exhibit marked pleomorphism (variation in size/shape) and high mitotic activity, which is a far more severe and characteristic change than the adaptive cell substitution seen in the lung's lining.

Choice C rationale

Dysplasia involves deranged cellular growth, resulting in cells that vary in size, shape, and organization, and often signifies a pre-cancerous condition. The change in the smoker's lung (columnar to squamous) is typically a protective response, called metaplasia, which may progress to dysplasia but is not dysplasia itself initially.

Choice D rationale

Metaplasia is an adaptive reversible change where one differentiated adult cell type (in this case, ciliated columnar epithelium) is replaced by another differentiated adult cell type (stratified squamous epithelium). This is a protective response to chronic irritation, such as cigarette smoke, as the squamous cells are more robust, though they sacrifice the important function of mucous clearance.